Palatin Technologies (NYSEAMERICAN:PTN) Announces Earnings Results

Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) issued its earnings results on Monday. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.58), reports. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $1.79 million.

Palatin Technologies Stock Performance

Shares of PTN stock traded down $0.01 on Wednesday, hitting $5.35. 5,466 shares of the stock traded hands, compared to its average volume of 35,372. The company’s fifty day moving average is $7.93 and its 200 day moving average is $13.39. Palatin Technologies has a 1-year low of $4.51 and a 1-year high of $31.00.

Palatin Technologies Company Profile

(Get Free Report)

Palatin Technologies is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, which are involved in processes such as inflammation, immune response and appetite regulation. Its research has included peptide-based treatments for inflammatory and other medical conditions. The company is best known for developing bremelanotide, marketed as Vyleesi, which the U.S. Food and Drug Administration approved in 2019 to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.

See Also

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.